PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 6, 2026Journal of Clinical Medicine0 citationsOpen Access

Convergent Hybrid Ablation and Concomitant Left Atrial Appendage Exclusion for Stroke Prevention and Rhythm Control in Persistent Atrial Fibrillation

View Full Paper
YTYonas R. TomaSDSune DamgaardCCChristian L. Carranza

Key Points

  • This research investigates the safety and efficacy of hybrid ablation combined with left atrial appendage exclusion in patients with persistent atrial fibrillation.
  • Conducted a single-center observational cohort study of 28 patients with symptomatic persistent AF.
  • Patients were refractory, 82.1% had failed at least one endocardial catheter ablation.
  • The procedure included epicardial ablation, thoracoscopic LAA exclusion (AtriClip), and endocardial catheter ablation.
  • LAA exclusion was successfully performed in 96.4% of patients.
  • Zero procedure-related strokes or deaths were reported, indicating acceptable safety.
  • Freedom from AF was achieved in 75.0% of patients at 12 months.
  • 50.0% of patients were free from any atrial arrhythmia off anti-arrhythmic drugs.
  • 32.1% required catheter ablation within 12 months to maintain sinus rhythm.

Abstract

Background/Objectives: Persistent and long-standing persistent atrial fibrillation (AF) presents a therapeutic clinical challenge balancing complex rhythm management with a heightened stroke risk. The left atrial appendage (LAA) is the primary source of thromboembolisms in these patients. This study evaluated the safety and efficacy of combining LAA exclusion with Convergent Hybrid Ablation for stroke prevention and rhythm control in a refractory patient cohort. Methods: A single-center observational cohort study was conducted including 28 patients with symptomatic persistent or long-standing persistent AF. The cohort was highly refractory, with 82.1% having failed at least one endocardial catheter ablation. The hybrid procedure consisted of sub-xiphoid epicardial ablation, thoracoscopic LAA exclusion (AtriClip), and endocardial catheter ablation. Safety and efficacy were assessed at 3 months and 12 months. Results: LAA exclusion was successfully performed in 96.4% of patients. The peri-operative safety profile was acceptable, with zero procedure-related strokes or deaths. At the 12-month follow-up, the rate of stroke or any other major adverse events was at 0.0%. Freedom from AF was 75.0%, shown by a 12-lead electrocardiography (ECG). Freedom from any atrial arrhythmia off anti-arrhythmic drugs (AADs) was achieved in 50.0% of patients. A total of 32.1% of the cohort required catheter ablation within 12 months to maintain sinus rhythm as part of the hybrid treatment. Conclusions: Concomitant LAA exclusion during Convergent Hybrid Ablation is a safe procedure with a high clinical success rate in maintaining sinus rhythm in a highly complex AF patient group. While no thromboembolic events were observed at 12 months, larger studies with longer follow-up are needed to confirm the potential for long-term stroke risk reduction. The findings suggest that for many patients, the hybrid procedure should be viewed as part of a multi-step strategy often requiring endocardial “touch-up” ablation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Toma et al. (2026) studied this question.

synapsesocial.com/papers/69faa30204f884e66b533ae8https://doi.org/10.3390/jcm15093440
Ask AI
Helpful
Bookmark
Share
View Full Paper